Our top pick for
Beginners
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Organogenesis stock
Own Organogenesis stock in just a few minutes.
Fact checked
Organogenesis Holdings Inc is a drug manufacturers-specialty & generic business based in the US. Organogenesis shares (ORGO) are listed on the NASDAQ and all prices are listed in US Dollars. Organogenesis employs 835 staff and has a trailing 12-month revenue of around USD$306.1 million.
How to buy shares in Organogenesis
- Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
- Search for Organogenesis. Find the stock by name or ticker symbol: ORGO. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Organogenesis reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Organogenesis, depending on your broker.
- Check in on your investment. Congratulations, you own a part of Organogenesis. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
Organogenesis share price
Use our graph to track the performance of ORGO stocks over time.Organogenesis shares at a glance
Information last updated 2021-03-03.
| 52-week range | USD$2.4722 - USD$17.11 |
|---|---|
| 50-day moving average | USD$12.1072 |
| 200-day moving average | USD$6.5649 |
| Wall St. target price | USD$14.5 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | USD$-0.581 |
Buy Organogenesis shares from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Organogenesis stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Is Organogenesis under- or over-valued?
Valuing Organogenesis stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Organogenesis's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Organogenesis's EBITDA
Organogenesis's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$11.5 million.
The EBITDA is a measure of a Organogenesis's overall financial performance and is widely used to measure a its profitability.
Organogenesis financials
| Revenue TTM | USD$306.1 million |
|---|---|
| Operating margin TTM | 1.27% |
| Gross profit TTM | USD$185 million |
| Return on assets TTM | 1.16% |
| Return on equity TTM | -12.63% |
| Profit margin | -1.62% |
| Book value | $0.609 |
| Market capitalisation | USD$2.1 billion |
TTM: trailing 12 months
Shorting Organogenesis shares
There are currently 1.0 million Organogenesis shares held short by investors – that's known as Organogenesis's "short interest". This figure is 0.7% up from 1.0 million last month.
There are a few different ways that this level of interest in shorting Organogenesis shares can be evaluated.
Organogenesis's "short interest ratio" (SIR)
Organogenesis's "short interest ratio" (SIR) is the quantity of Organogenesis shares currently shorted divided by the average quantity of Organogenesis shares traded daily (recently around 1.0 million). Organogenesis's SIR currently stands at 0.99. In other words for every 100,000 Organogenesis shares traded daily on the market, roughly 990 shares are currently held short.
However Organogenesis's short interest can also be evaluated against the total number of Organogenesis shares, or, against the total number of tradable Organogenesis shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Organogenesis's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Organogenesis shares in existence, roughly 10 shares are currently held short) or 0.0154% of the tradable shares (for every 100,000 tradable Organogenesis shares, roughly 15 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Organogenesis.
Find out more about how you can short Organogenesis stock.
Organogenesis share dividends
We're not expecting Organogenesis to pay a dividend over the next 12 months.
Organogenesis share price volatility
Over the last 12 months, Organogenesis's shares have ranged in value from as little as $2.4722 up to $17.11. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Organogenesis's is 1.5354. This would suggest that Organogenesis's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Organogenesis overview
Organogenesis Holdings Inc., a regenerative medicine company, focuses on the development, manufacture, and commercialization of solutions for the advanced wound care, and surgical and sports medicine markets primarily in the United States. The company's advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for treating DFUs; PuraPly AM to address biofilm across a range of wound types; and Affinity and NuShield to address various wound sizes and types. Its surgical and sports medicine products comprise ReNu for in-office joint and tendon applications; NuCel for bony fusion in the spine and extremities; NuShield and Affinity for surgical applications in targeted soft tissue repairs; and PuraPly AM for the surgical treatment of open wounds. The company's pipeline products include TransCyte for the treatment of second- and third-degree burns; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; Novachor for the treatment of chronic and acute wounds; Gintuit for the treatment of mucogingival conditions in adults; and PuraPly XT and PuraPly MZ for the treatment of chronic and acute wounds, as well as for surgical treatment of open wounds. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices. The company sells its products through direct sales representatives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.
Frequently asked questions
More guides on Finder
-
How to buy Achilles Therapeutics plc (ACHL) stock when it goes public
Everything we know about the Achilles Therapeutics plc IPO, plus information on how to buy in.
-
How to buy SEMrush Holdings Inc (SEMR) stock when it goes public
Everything we know about the SEMrush Holdings Inc IPO, plus information on how to buy in.
-
How to buy ChargePoint (ORGO.US) stock when it goes public
Everything we know about the ChargePoint IPO, plus information on how to buy in.
-
How to buy Kaltura Inc (KLTR) stock when it goes public
Everything we know about the Kaltura Inc IPO, plus information on how to buy in.
-
How to buy Rocket Lab (ORGO.US) stock when it goes public
Everything we know about the Rocket Lab IPO, plus information on how to buy in.
-
How to buy Soho House (ORGO.US) stock when it goes public
Everything we know about the Soho House IPO, plus information on how to buy in.
-
How to buy VIZIO (VZIO) stock when it goes public
Everything we know about the VIZIO IPO, plus information on how to buy in.
-
How to buy IDW Media Holdings Inc (IDW) stock when it goes public
Everything we know about the IDW Media Holdings Inc IPO, plus information on how to buy in.
-
How to buy Karooooo Ltd (KARO) stock when it goes public
Everything we know about the Karooooo Ltd IPO, plus information on how to buy in.
-
How to buy Connect Biopharma Holdings Limited (CNTB) stock when it goes public
Everything we know about the Connect Biopharma Holdings Limited IPO, plus information on how to buy in.
Ask an Expert